ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Organogenesis Holdings Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

CANTON, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will attend in the 9th Annual SVB Leerink Global Healthcare Conference at the Lotte New York Palace in New York, New York and participate in a fireside chat on Wednesday, February 26 at 3:30 p.m. Eastern Time.

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website . An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
 
443-213-0500

Press and Media Inquiries:
Organogenesis
Marcus Girolamo
  
817-688-4767
EN
21/02/2020

Underlying

ORGOOrganogenesis Holdings (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2...

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m....

February 19, 2026 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Announces Initiation of Biologics License Application fo...

Organogenesis Announces Initiation of Biologics License Application for ReNu® Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administ...

December 23, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Announces Successful FDA Meeting and Plan to File BLA fo...

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administra...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Summary: Net product revenue of $150.5 million for the third quarter o...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch